Detalles de la búsqueda
1.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37248424
2.
Genetic Basis and Therapies for Vascular Anomalies.
Circ Res
; 129(1): 155-173, 2021 06 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34166070
3.
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
BMC Cancer
; 21(1): 1292, 2021 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34856936
4.
Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Curr Treat Options Oncol
; 22(1): 7, 2020 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269438
5.
Rapamycin and treatment of venous malformations.
Curr Opin Hematol
; 26(3): 185-192, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30855337
6.
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Oncologist
; 21(12): 1416-e17, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27903924
7.
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
BJU Int
; 118(3): 408-15, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26779597
8.
Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review.
Pharmaceuticals (Basel)
; 17(4)2024 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38675461
9.
Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus.
Orphanet J Rare Dis
; 19(1): 199, 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38750525
10.
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
Clin Genitourin Cancer
; 22(2): 305-314.e3, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38087702
11.
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Target Oncol
; 2024 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38704759
12.
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Eur Urol Oncol
; 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575409
13.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Eur Urol Oncol
; 7(1): 102-111, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37481365
14.
The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy.
Curr Oncol
; 30(12): 10550-10555, 2023 12 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38132404
15.
Regression of a melanoma brain metastasis that had appeared after immune checkpoint inhibitor discontinuation: a hypothesis-generating case.
Acta Clin Belg
; 78(6): 516-520, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466163
16.
Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations.
JCI Insight
; 8(21)2023 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37937645
17.
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Clin Exp Med
; 23(8): 5413-5422, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37917218
18.
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Minerva Urol Nephrol
; 75(4): 460-470, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37530662
19.
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Target Oncol
; 18(4): 559-570, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37369815
20.
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Clin Genitourin Cancer
; 21(5): e309-e319.e1, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062658